Exact Mass: 929.4534478
Exact Mass Matches: 929.4534478
Found 31 metabolites which its exact mass value is equals to given mass value 929.4534478,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
[D-Lys3]-GHRP-6
C49H63N13O6 (929.5024017999999)
Crustacean erythrophore concentrating hormone
C45H59N11O11 (929.4395304000001)
PGP(i-12:0/LTE4)
PGP(i-12:0/LTE4) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/LTE4), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
PGP(LTE4/i-12:0)
PGP(LTE4/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(LTE4/i-12:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).
p-Glu-Leu-Asn-Phe-Ser-Pro-Gly-Trp-NH2|pELNFSPGW-NH2|pELNFSPGWamide|red pigment concentrating hormone|RPCH
C45H59N11O11 (929.4395304000001)
(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide
C46H75NO18 (929.4983890000001)
(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide
C46H75NO18 (929.4983890000001)
(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxydodeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide
C46H75NO18 (929.4983890000001)
8-benzyl-3,6,9,13,16,20-hexahydroxy-18-[(1e,3e)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-1,5,15,19-tetramethyl-2-methylidene-25-oxo-1,4,7,10,14,17,21-heptaazacyclopentacosa-3,6,9,13,16,20-hexaene-11,22-dicarboxylic acid
(2s)-2-({[(3s,6r,9r,12s,15r)-3,12-bis[(2s)-butan-2-yl]-2,5,8,11-tetrahydroxy-6,9-bis[2-(4-hydroxyphenyl)ethyl]-13-methyl-14-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,7,10-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid
2-({[5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid
(10s,13s,16s,19s,22s,25s,26r)-22-[(2r)-butan-2-yl]-13-(3-carbamimidamidopropyl)-12,15,18,21,24-pentahydroxy-25-({hydroxy[(2s)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]methylidene}amino)-19,26-diisopropyl-3,5,7,11,14,17,20,23-octaazapentacyclo[14.13.2.1²,²⁷.1⁵,⁸.0⁴,³⁰]tritriaconta-1(29),2(32),4(30),6,8(33),11,14,17,20,23,27-undecaene-10-carboxylic acid
3-(4-hydroxyphenyl)-2-[({2,5,11,14-tetrahydroxy-6,9-bis[2-(4-hydroxyphenyl)ethyl]-7-methyl-8-oxo-3,12-bis(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]propanoic acid
(10r,13s,16s,19s,22s,25s,26r)-13-(3-carbamimidamidopropyl)-12,15,18,21,24-pentahydroxy-25-({hydroxy[(2s)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]methylidene}amino)-19,26-diisopropyl-22-(2-methylpropyl)-3,5,7,11,14,17,20,23-octaazapentacyclo[14.13.2.1²,²⁷.1⁵,⁸.0⁴,³⁰]tritriaconta-1(29),2(32),4(30),6,8(33),11,14,17,20,23,27-undecaene-10-carboxylic acid
(2s,3s)-2-({[(3s,6s,9s,12s,15r)-3-[(acetyloxy)methyl]-2,5,11,14-tetrahydroxy-6-[2-(4-hydroxyphenyl)ethyl]-12-(2-methanesulfonylethyl)-7-methyl-8-oxo-9-(2-phenylethyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-methylpentanoic acid
C44H63N7O13S (929.4204348000001)
(2s)-2-({[(3s,6s,9s,15r)-3,12-bis[(2s)-butan-2-yl]-2,5,11,14-tetrahydroxy-6,9-bis[2-(4-hydroxyphenyl)ethyl]-7-methyl-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-(4-hydroxyphenyl)propanoic acid
13-(3-carbamimidamidopropyl)-12,15,18,21,24-pentahydroxy-25-{[hydroxy(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)methylidene]amino}-19,26-diisopropyl-22-(2-methylpropyl)-3,5,7,11,14,17,20,23-octaazapentacyclo[14.13.2.1²,²⁷.1⁵,⁸.0⁴,³⁰]tritriaconta-1(29),2(32),4(30),6,8(33),11,14,17,20,23,27-undecaene-10-carboxylic acid
2-[({3-[(acetyloxy)methyl]-2,5,11,14-tetrahydroxy-6-[2-(4-hydroxyphenyl)ethyl]-12-(2-methanesulfonylethyl)-7-methyl-8-oxo-9-(2-phenylethyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-methylpentanoic acid
C44H63N7O13S (929.4204348000001)